Decision: Favourable
Study Title:
Single arm phase 2 trial of neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a standard chemotherapy-sparing approach to curative-intent treatment – SHAMROCK study
NREC Code:
23-NREC-MD-022
Decision:
Favourable
Meeting Date:
20/07/2023
Study Type:
MD Application
Principal Investigator:
Prof. Bryan Hennessy
PI Institution:
Beaumont Hospital
Sponsor:
Cancer Trials Ireland